If you have struggled with severe acne, you may already know isotretinoin as one of the most important medicines available when other appropriate treatments have not worked. Its introduction transformed the treatment of severe nodular and cystic acne by giving dermatologists an option capable of producing substantial improvement and, for some people, prolonged remission after treatment ends.
Its history also shows why effectiveness cannot be considered separately from safety. Research established isotretinoin’s powerful effects on acne, but experience also revealed major pregnancy risks and the need for increasingly structured monitoring. If isotretinoin is considered for you today, your treatment should therefore involve careful specialist assessment, counselling and follow-up.
What Is Isotretinoin?
Isotretinoin is an oral retinoid related to vitamin A and is also known chemically as 13-cis-retinoic acid. If you take isotretinoin, it acts on several processes involved in acne, particularly sebaceous-gland activity and sebum production, while also influencing follicular skin-cell behaviour and inflammation.
In current UK practice, you may be considered for oral isotretinoin if you are over 12 and your severe acne has not responded adequately to appropriate courses of systemic antibiotics and topical treatment. Your dermatologist may consider it for conditions such as nodulo-cystic acne, acne conglobata, acne fulminans or severe acne that puts you at risk of permanent scarring. If your acne is mild and uncomplicated, isotretinoin would not normally be your first treatment.
Acne Treatment Before Isotretinoin
Before isotretinoin became available, severe cystic acne could be extremely difficult to control, particularly when established treatments failed to provide lasting improvement. You may have needed repeated courses of treatment, yet painful inflammation and persistent breakouts could continue.
If your severe acne continued despite treatment, you could also face an increasing risk of progressive and permanent scarring. With fewer effective options available at the time, you may have found difficult acne a significant and long-term challenge to control.
How Did Isotretinoin Research Begin?
Before isotretinoin became established as an acne medicine, researchers were studying retinoids for their biological effects in other areas of medicine. Work involving 13-cis-retinoic acid at Roche during the 1960s formed part of this wider retinoid research and helped establish the compound that would later become important in dermatology.
Its value in severe acne became clearer through clinical research during the 1970s. These investigations ultimately shifted isotretinoin from an experimental retinoid into a medicine capable of changing how dermatologists approached previously difficult-to-control acne. If you are treated with isotretinoin today, you are benefiting from this shift from experimental retinoid research to a treatment specifically studied for severe acne.
How Retinoid Research Opened a New Direction
Research into retinoids encouraged scientists to explore how vitamin A-related compounds could influence skin cells and sebaceous glands. This work helped researchers better understand how these compounds might affect the processes involved in acne development.
Isotretinoin eventually stood out because of its ability to affect several processes that contribute to severe acne. If you have persistent acne that has not responded to other appropriate treatments, this broader action helps explain why isotretinoin may offer your dermatologist a different treatment approach.
The Breakthrough Study of 1979
A landmark study published in the New England Journal of Medicine in 1979 treated 14 people with treatment-resistant cystic and conglobate acne with oral 13-cis-retinoic acid for four months. Thirteen experienced complete clearing, while the remaining participant had a 75% improvement.
The researchers also reported remission lasting for as long as 20 months after treatment had stopped at the time of publication. These were striking early findings, but you should remember that this was a very small study and its results should not be interpreted as a guarantee of the outcome you would experience today.
Why Those Early Results Were So Important
The early results attracted attention because isotretinoin appeared to provide benefits that could continue after treatment ended. This suggested that severe acne could sometimes enter a longer period of remission rather than simply improving while you took the medicine.
- Lasting improvement: Acne could remain better for months after treatment stopped.
- Longer remission: Some people experienced a prolonged period with fewer or no severe acne flare-ups.
- Difficult acne: The results were especially important for people whose severe acne had not responded well to other treatments.
- Treatment approach: These findings changed how dermatologists viewed persistent and severe acne.
The possibility of longer-lasting improvement made isotretinoin an important development in acne treatment. If you have severe acne that remains difficult to control, you can see why a treatment capable of producing improvement beyond the treatment period represented such an important change.
How Did Researchers Discover Isotretinoin’s Effect on Sebum?
Researchers soon demonstrated one of isotretinoin’s most important biological effects: a substantial reduction in your skin’s sebum production. This matters because sebaceous-gland activity is an important part of acne development.
A 1980 controlled study of people with very severe acne reported a 75% reduction in sebum excretion after four weeks and substantial clinical improvement after four months. The study also identified dose-related side effects, particularly dryness affecting the skin and mucous membranes. If you take isotretinoin today, this reduction in sebum helps explain both the improvement you may see in your acne and some of the dryness you may experience during treatment.
FDA Approval Arrived in 1982
Following the early clinical research, isotretinoin received US approval in 1982 for severe acne and was marketed by Hoffmann-La Roche under the brand name Accutane. This allowed the treatment to become much more widely available to people with severe acne that had not responded adequately to conventional therapy.
The approval represented a major change in acne treatment, but important safety concerns were already recognised. The medicine’s potential to harm a developing baby meant pregnancy warnings became part of its prescribing history from an early stage.
Isotretinoin Changed Expectations for Severe Acne
The introduction of isotretinoin transformed what you could potentially expect from treatment when severe acne had not responded adequately to antibiotics or other conventional therapies. If you were an appropriate candidate, treatment could offer substantial and prolonged improvement, giving your dermatologist another option for persistent and difficult-to-treat acne.
How Isotretinoin Changed Severe Acne Treatment
| Aspect | Before Isotretinoin | Impact of Isotretinoin | Why It Mattered |
| Severe acne treatment | Often relied on antibiotics and other conventional therapies | Offered another option for severe, persistent acne | Expanded treatment possibilities |
| Response to treatment | Some approaches provided limited or temporary improvement | Could produce substantial improvement in selected patients | Changed expectations for treatment outcomes |
| Repeated breakouts | Management often focused on controlling recurring acne | Could provide prolonged improvement after treatment | Shifted the focus beyond repeated breakout control |
| Treatment-resistant acne | Options were more limited when conventional treatments failed | Provided an effective option for appropriately selected patients | Helped address difficult-to-treat acne |
| Dermatology practice | Focused heavily on managing ongoing symptoms | Introduced a treatment capable of producing longer-lasting improvement | Changed approaches to severe acne management |
| Long-term outlook | Recurring disease could remain difficult to control | Some patients experienced prolonged improvement | Improved expectations for suitable patients |
Its Effects Go Beyond Reducing Oil
If you take isotretinoin, the medicine affects several processes involved in your acne rather than targeting only one part of the condition. It can reduce your sebaceous-gland activity and sebum production, helping limit one of the key factors contributing to your breakouts.
The medicine also influences how your skin cells behave and affects inflammatory processes involved in acne development. By acting on several pathways at once, isotretinoin can provide a broader effect than treatments that focus mainly on a single aspect of acne.
Long-Term Remission Became Possible
One of isotretinoin’s major contributions to acne treatment is that your improvement may continue after the course has finished. This differs from many treatments that primarily suppress acne while you continue using them.
Your acne can still return after isotretinoin, and some people require further treatment or another course. You should therefore think of isotretinoin as a medicine capable of producing prolonged remission rather than as a guaranteed permanent cure.
It Also Changed the Approach to Acne Scarring
Severe inflammatory acne can produce permanent scarring, so controlling your active disease before additional scars develop can be an important treatment goal. Isotretinoin gave dermatologists an important option when severe acne was continuing despite appropriate standard treatments or when your risk of permanent scarring was substantial.
Isotretinoin does not remove scars that have already formed. Once your active acne has been controlled, your dermatologist can assess established scarring separately and discuss whether another treatment may be appropriate.
Pregnancy Risks Became a Major Safety Issue
Isotretinoin is highly teratogenic, which means exposure during pregnancy can cause serious harm to a developing baby. Reports after the medicine entered wider clinical use reinforced the importance of preventing pregnancy throughout treatment.
If you could become pregnant, your current UK treatment must follow the applicable Pregnancy Prevention Programme. You should never take isotretinoin during pregnancy and should follow the pregnancy-testing and contraception instructions given by your prescriber.
Why Did Isotretinoin Need Stronger Safety Programmes?
As isotretinoin use expanded, regulators introduced progressively more structured measures designed to make sure you understand its important risks before treatment begins. Pregnancy prevention became a major part of these safeguards, while later measures also strengthened information and monitoring relating to other potential adverse effects.
If you are prescribed isotretinoin today, your care involves much more than simply receiving a prescription. You should receive appropriate information about the risks, have relevant health concerns assessed before treatment and continue to be monitored while you take isotretinoin.
Isotretinoin Prescribing Continues to Evolve
UK isotretinoin safety requirements changed again on 22 January 2026. The previous regulatory requirement for a second independent healthcare professional to approve treatment for someone under 18 was removed and replaced by alternative risk-minimisation measures.
Current safeguards include an updated Acknowledgement of Risk Form, a Patient Reminder Card and a patient information video that should be viewed before treatment begins. Mental health should be assessed before prescribing, sexual-function concerns should be discussed, and both areas should continue to be monitored during follow-up. If you could become pregnant, the Pregnancy Prevention Programme remains in place.
Why Specialist Acne Assessment Matters
Isotretinoin is not appropriate for everyone with acne. Your specialist should assess the severity of your acne, your risk of permanent scarring, which appropriate treatments you have already tried and your medical and mental-health history before deciding whether the medicine is clinically indicated.
If you are considering specialist treatment through an acne clinic in London, your consultation can also help you understand the current safety requirements, expected benefits and possible adverse effects. You should have an opportunity to ask questions and discuss alternatives before deciding whether treatment is right for you.
Why Does Isotretinoin Still Matter in Dermatology Today?
More than four decades after its introduction for acne, isotretinoin continues to play an important role in managing severe or treatment-resistant acne. Its lasting influence comes from its ability to address several major processes involved in acne rather than focusing on just one factor.
If you are an appropriate candidate for isotretinoin, you may experience substantial and sustained improvement even after your treatment course has ended. This possibility of longer-lasting results, together with the medicine’s effects on several acne pathways, helps explain why it may still be considered when your severe acne has not responded adequately to other treatments.
Myth vs Fact
| Myth | What You Should Know |
| Isotretinoin was first developed in 1979. | If you look back before the landmark 1979 acne study, isotretinoin had already emerged from earlier retinoid research. |
| The original study proved isotretinoin permanently cures acne. | Early studies showed prolonged remission, but this does not mean you can expect a guaranteed permanent cure. |
| Isotretinoin only reduces oiliness. | Isotretinoin affects several processes involved in acne, so if you take it, its effects go beyond simply reducing oiliness. |
| Isotretinoin can remove acne scars that already exist. | Your treatment controls active acne and may reduce further scarring risk, but established scars need separate assessment. |
| Isotretinoin became known to be dangerous in pregnancy only recently. | Isotretinoin’s teratogenic risk became a major safety concern early in its clinical history, which is why you must not take it during pregnancy. |
| Isotretinoin safety checks only concern pregnancy. | Your current UK monitoring also includes mental-health and sexual-function considerations. |
| Everyone under 18 now needs two prescribers to approve isotretinoin. | If you are under 18, the previous UK requirement for a second independent healthcare professional to approve your treatment no longer applies; it was removed in January 2026 and replaced by other safeguards. |
| Any acne can be treated with isotretinoin as a first option. | If you are considering isotretinoin, it is generally reserved for appropriately selected severe acne after suitable standard treatments have not worked. |
Key Takeaways
- If you are prescribed isotretinoin, you are taking an oral retinoid known chemically as 13-cis-retinoic acid.
- Its development grew from retinoid research carried out before it became an established acne treatment.
- A landmark 1979 study treated 14 people with severe treatment-resistant acne.
- Thirteen of those 14 participants experienced complete clearing during the study.
- A 1980 study found a 75% reduction in sebum excretion after four weeks of treatment.
- Isotretinoin received its first US approval in 1982.
- Your treatment can produce prolonged remission, but it cannot guarantee that your acne will never return.
- If isotretinoin is being considered for you, its important adverse effects are one reason your specialist will first confirm that the treatment is appropriate for your severe acne.
- You must not take isotretinoin during pregnancy because it can seriously harm a developing baby.
- Your current UK treatment includes specific risk information and monitoring for mental-health, sexual-function and pregnancy-related safety where relevant.
UK Guidance Note
In current UK practice, you should generally be considered for oral isotretinoin only when you are over 12 and have severe acne that has not responded to adequate courses of appropriate systemic antibiotics and topical treatment. Your risk of permanent scarring can also be an important reason for specialist referral and consideration of isotretinoin.
Before starting treatment, you should receive information about isotretinoin’s potential benefits, risks and alternatives and complete the applicable risk-minimisation process. Your mental health should be assessed before prescribing, sexual-function concerns should be discussed, and these areas should continue to be monitored during treatment. Current UK safeguards also include the Acknowledgement of Risk Form, Patient Reminder Card and patient information video. If you could become pregnant, you must also follow the Pregnancy Prevention Programme.
Frequently Asked Questions
1. When did isotretinoin become an acne treatment?
Isotretinoin emerged from earlier retinoid research, with important acne studies appearing during the 1970s. If you use the treatment today, you are benefiting from decades of subsequent research into its effectiveness and safety.
2. What did the landmark 1979 isotretinoin study find?
Thirteen of the 14 participants experienced complete clearing during treatment, while the remaining participant improved by 75%. You should interpret these findings as important historical evidence rather than a prediction of your individual outcome.
3. When was isotretinoin approved for acne?
Isotretinoin received its initial US approval in 1982 and was marketed by Hoffmann-La Roche as Accutane for severe acne.
4. Why was isotretinoin such an important breakthrough?
Isotretinoin can act on several important processes involved in severe acne, which means you may experience broader effects than with treatments targeting only one part of acne development.
5. Can isotretinoin permanently cure your acne?
No permanent cure can be guaranteed. Your acne may remain in remission for a prolonged period after treatment, but it can return and you may require further management.
6. Can isotretinoin prevent your acne scars?
By controlling severe active inflammation, your treatment may reduce your risk of developing further permanent scars. It does not remove scars that have already formed.
7. Why must you avoid pregnancy while taking isotretinoin?
Isotretinoin can cause serious harm to a developing baby. If you could become pregnant, you must follow the Pregnancy Prevention Programme and the instructions provided by your prescriber.
8. How did UK isotretinoin rules change in 2026?
In January 2026, the previous requirement for two independent healthcare professionals to approve treatment for someone under 18 was removed. If you are treated with isotretinoin in the UK, you still remain subject to the other strengthened risk-minimisation, counselling and monitoring requirements.
9. Are mental-health effects monitored during your isotretinoin treatment?
Yes. Your mental health should be assessed before treatment and monitored during follow-up. You should tell your prescriber promptly if you experience concerning changes in your mood, thoughts or mental wellbeing.
10. Why do you need specialist assessment before isotretinoin?
Your specialist needs to decide whether your acne is sufficiently severe, whether appropriate previous treatment has been tried and whether your individual risks make isotretinoin suitable. Your treatment also requires specific counselling and monitoring.
Final Thoughts: How Isotretinoin Changed Acne Treatment
The history of isotretinoin shows how decades of retinoid research developed into a treatment that substantially changed the management of severe and treatment-resistant acne. Early studies demonstrated major reductions in acne severity and sebum production, while subsequent experience established both the possibility of prolonged remission and the importance of careful safety monitoring.
If you are considering treatment through a specialist acne clinic in London, contact the London Dermatology Centre to arrange an individual assessment and discuss whether isotretinoin or another treatment may be appropriate for you.
References:
- Jones, H., Blanc, D. and Cunliffe, W.J. (1980) ‘13-cis retinoic acid and acne’, The Lancet, 2(8203), pp. 1048–1049. Available at: https://pubmed.ncbi.nlm.nih.gov/6107678/
- Khan, A., Khan, C. and Ahmed, S. (2026) ‘The history, development and current status of isotretinoin: a review article’, Clinical and Experimental Dermatology, 51(6), pp. 939–950. Available at: https://pubmed.ncbi.nlm.nih.gov/41378746/
- Lammer, E.J. et al. (1985) ‘Retinoic acid embryopathy’, The New England Journal of Medicine, 313(14), pp. 837–841. Available at: https://pubmed.ncbi.nlm.nih.gov/3162101/
- Layton, A. (2009) ‘The use of isotretinoin in acne’, Dermato-Endocrinology, 1(3), pp. 162–169. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC2835909/
- Peck, G.L. et al. (1979) ‘Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid’, The New England Journal of Medicine, 300(7), pp. 329–333. Available at: https://pubmed.ncbi.nlm.nih.gov/153472/